• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Meta-analysis links pegylated interferon to higher hepatitis B clearance

by
November 13, 2026
in Health
Reading Time: 5 mins read
0
Meta-analysis links pegylated interferon to higher hepatitis B clearance

Meta-analysis links pegylated interferon to higher hepatitis B clearance

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comprehensive systematic review and meta-analysis published in the Chinese Medical Journal demonstrates that pegylated interferon-alpha therapy significantly enhances the clearance of hepatitis B surface antigen in various populations with chronic hepatitis B virus infection. The study, conducted by Professor Enqiang Chen from West China Hospital and a team of researchers, provides critical evidence supporting personalized treatment strategies by evaluating treatment outcomes across different chronic infection groups. The findings were made available online on August 24, 2026, and address a significant gap in prior research, which had largely concentrated on single-dimensional analyses of specific subgroups rather than offering a comprehensive evaluation of the overall treatment population.

Chronic hepatitis B virus infection remains a major global public health challenge, particularly prevalent in endemic regions of Asia and sub-Saharan Africa. Achieving a functional cure is widely recognized as a key goal in managing this condition, as it can significantly reduce the risk of end-stage liver disease and improve patients’ quality of life. Hepatitis B surface antigen clearance or seroconversion serves as the primary indicator of this functional cure. However, spontaneous clearance of the antigen is rare, with an annual rate of only about 1% observed in both children and adults. Consequently, therapy based on pegylated interferon-alpha is currently regarded as one of the most promising options for attaining clinical cure, yet a holistic understanding of its efficacy across diverse patient groups was previously lacking.

To address this gap, the research team conducted the first comprehensive systematic review and meta-analysis summarizing hepatitis B surface antigen clearance and seroconversion rates. The analysis encompassed different chronic hepatitis B infections at various treatment durations and follow-up periods after therapy discontinuation. By aggregating data from a wide range of studies, the researchers aimed to elucidate the sources of variability in treatment outcomes. This approach allowed for a more nuanced understanding of how different patient characteristics and treatment protocols influence the likelihood of achieving antigen clearance, moving beyond the limitations of isolated subgroup analyses.

The meta-analysis revealed that pegylated interferon-alpha therapy achieves markedly higher clearance rates compared to spontaneous clearance or long-term nucleos(t)ide analog therapy. For instance, in inactive hepatitis B surface antigen carriers, the therapy achieves an antigen clearance rate of 57%, which stands in stark contrast to the 1.54% rate observed in patients on nucleos(t)ide analog monotherapy or untreated cohorts. In children with chronic hepatitis B, the treatment increases the clearance rate to 22%, a figure that is substantially higher than the spontaneous annual clearance rate of approximately 1% seen in untreated children. These findings highlight the superior efficacy of interferon-based therapy in specific patient populations.

Among nucleos(t)ide analog-treated chronic hepatitis B patients, the study found that individuals who were hepatitis B surface antigen-negative tended to exhibit higher clearance rates. Specifically, in patients with baseline antigen levels of 1500 IU/mL or lower, clearance rates could reach up to 35%, while those with levels below 1000 IU/mL saw rates as high as 45%. In contrast, the clearance rate associated with nucleos(t)ide analog monotherapy remains low, averaging approximately 0.22% per year, which amounts to only about 2.11% over a 10-year period.

The research team also conducted subgroup analyses focusing on Asian populations, which were predominantly Chinese, and other ethnic groups. Asian experts, who accounted for 72% of the included studies, have been pioneers in recognizing the significance of antigen clearance. Over nearly two decades of clinical experience, extensive research has been conducted on pegylated interferon-alpha across different infection populations. The rates of antigen clearance and seroconversion in Asian patients were found to be 21% and 18%, respectively.

Chronic hepatitis B is characterized by profound clinical heterogeneity, influenced by both viral and host immune factors. To elucidate the sources of this variability, the researchers performed a meta-regression analysis. This statistical approach revealed that heterogeneity was partially explained by treatment strategy, publication year, baseline hepatitis B e-antigen status, and study design. Clinically, these findings highlight that combining pegylated interferon-alpha with nucleos(t)ide analogs significantly improves the likelihood of achieving antigen clearance compared to interferon monotherapy.

Furthermore, the analysis identified specific predictors of favorable outcomes. Treatment duration beyond 48 weeks and a baseline hepatitis B e-antigen-negative status were found to be strong predictors of successful clearance. These factors provide a data-driven framework for precision hepatitis B management and patient stratification, allowing clinicians to tailor treatment plans based on individual patient characteristics.

Despite the promising results, the study acknowledges that the antigen clearance rate in treatment-naive chronic hepatitis B patients is around 5%, indicating that there is still room for improvement in treatment efficacy. Ongoing research is exploring broader treatment populations and optimizing strategies to further enhance clearance rates. These strategies include extending therapy duration, implementing intermittent dosing, and utilizing combination regimens involving novel agents.

Preliminary evidence suggests that combining new drugs with pegylated interferon-alpha could yield promising results, although confirmation of sustained high rates of clearance requires further investigation. Professor Chen concluded that pegylated interferon-alpha remains the cornerstone in pursuing a functional cure for hepatitis B, providing an opportunity for antigen clearance in different chronic infection groups. Personalized treatment is key to maximizing the benefits of this therapy and improving long-term outcomes for patients worldwide.

The study was supported by Clinical Novel Techniques of West China Hospital of Sichuan University, as noted in the funding information for the research. The findings were published in the Chinese Medical Journal, a peer-reviewed publication issued by the Chinese Medical Journals Publishing House Co., Ltd. The specific article, titled “Hepatitis B surface antigen clearance rate with pegylated interferon-α therapy in different chronic hepatitis B virus infection populations: A systematic review and meta-analysis,” was made available online on August 24, 2026.

Professor Enqiang Chen, the lead researcher, serves as a Chief Physician and Medical Team Leader in Infectious Diseases at West China Hospital. His professional background includes specialization in complex liver and infectious diseases, and he holds the position of a reserve candidate for the Sichuan Province Academic and Technical Leader. Chen’s academic contributions extend to editorial roles in several journals, including Current Stem Cell Research & Therapy, Journal of Clinical and Translational Hepatology, BMC Infectious Diseases, and World Journal of Virology. He has led five national and provincial research projects and has authored over 100 papers indexed in the Science Citation Index, in addition to co-editing more than 10 professional books.

Subject of Research: Efficacy of pegylated interferon-alpha for hepatitis B surface antigen clearance in chronic hepatitis B virus infection

Article Title: Chinese Medical Journal article review explores hepatitis B surface antigen clearance rate in chronic hepatitis B virus infection treated with pegylated interferon-α

Article References: Chinese Medical Journal article review explores hepatitis B surface antigen clearance rate in chronic hepatitis B virus infection treated with pegylated interferon-α. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: hepatitis B, pegylated interferon, HBsAg clearance, meta-analysis, chronic hepatitis B, functional cure, nucleos(t)ide analogs, clinical trial, viral infection, liver disease, Chinese, Medical

News Source: Kristina Jarvis. (November 13, 2026). Meta-analysis links pegylated interferon to higher hepatitis B clearance. Scienmag.

Tags: Chinesechronic hepatitis Bclinical trialfunctional cureHBsAg clearancehepatitis Bliver diseasemedicalMeta-analysisnucleos(t)ide analogspegylated interferonviral infection
Share12Tweet7Share2ShareShareShare1

Related Posts

Comorbidities and Walking Difficulty Associated With Lower Quality of Life in MOGAD

Comorbidities and Walking Difficulty Associated With Lower Quality of Life in MOGAD

November 18, 2026
Salivary Antibiotic Monitoring Remains Investigational Despite Diagnostic Potential in Tuberculosis Care

Salivary Antibiotic Monitoring Remains Investigational Despite Diagnostic Potential in Tuberculosis Care

November 18, 2026

Elderly Patient Experiences Transient Myoclonic State Following General Anesthesia

November 18, 2026

Hospital Data Algorithm Improves Identification of Incarcerated Patients in California

November 18, 2026

POPULAR NEWS

  • Neural Network Inverse Design Optimizes Broadband Hybrid Plasmonic Leaky Wave Antenna

    Neural Network Inverse Design Optimizes Broadband Hybrid Plasmonic Leaky Wave Antenna

    29 shares
    Share 12 Tweet 7
  • Livestock Holdings and Agroecology Shape Carnivore Conservation Attitudes in Southern Ethiopia

    29 shares
    Share 12 Tweet 7
  • Researchers Identify GRAM Genes Across Cultivated Sweetpotato and Two Diploid Relatives

    29 shares
    Share 12 Tweet 7
  • Sensor Weighted Crop Simulations Significantly Improve Drone Maize Leaf Area Retrieval

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Comorbidities and Walking Difficulty Associated With Lower Quality of Life in MOGAD

Salivary Antibiotic Monitoring Remains Investigational Despite Diagnostic Potential in Tuberculosis Care

Elderly Patient Experiences Transient Myoclonic State Following General Anesthesia

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.